US perspective on the impact of Brexit on the pharmaceutical sector
Posted: 13 September 2018 | Daniel Kracov, Jacqueline Mulryne, Libby Amos | No comments yet
As the UK prepares to withdraw from the EU on 29th March 2019 at 23:00, this article delivers a US perspective on what Brexit is likely to mean for pharmaceutical companies.
It remains difficult for US companies to fully understand the risks and implications of Brexit.
The UK’s official withdrawal from the European Union, commonly known as Brexit, will occur on 29th March 2019 at 23:00. In anticipation, the UK and EU are currently negotiating what this means, for both sides, and the relationship between the two entities going forward.
What the final relationship will be is currently unknown, and as the rhetoric within the UK political spectrum increases, it is difficult for US companies to fully understand the risks and implications of Brexit. This article provides an overview of the impact of Brexit on life sciences companies in the US and outlines potential steps that such companies should be considering.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Issue
Related topics
Big Pharma, Brexit, Drug Supply Chain, Research & Development (R&D)
Related organisations
European Economic Area, European Medicines Agency., Medicines and Healthcare products Regulatory Agency
